About This Briefing

What Southern Peptide Co is

Southern Peptide Co is an independent editorial briefing covering the published research on three peptides grouped under Recovery & Tissue Repair, framed specifically through wound-healing and skin-barrier repair research: GHK-Cu, TB-500, and the research-community Wolverine blend that pairs TB-500 with BPC-157. GHK-Cu leads the briefing because it carries the deepest human evidence of the three.

The organizing habit here is a clinician's habit, not a marketer's: separate what is documented from what is reported, and what is reported from what is simply unknown. Each compound page states what has been studied, in which model — human, animal, or cell culture — states the mechanism as currently understood, and states plainly where the evidence stops. A single comparison page lines the three up side by side, and one shared references list aggregates every source cited across the whole site.

How it is compiled

Three habits govern what appears here.

First, quantitative claims are tied to a numbered citation. Every percentage, dose, sample size, or duration traces to a specific peer-reviewed source, collected on the references page with DOIs and PubMed links where available.

Second, evidence is described at its actual strength, not its marketed strength. A finding from a 45-person hair-growth trial is reported as a 45-person hair-growth trial, not as proof of a broader claim. Where a compound's most-cited data come from a different molecule — as with TB-500's human safety trial, which used full-length thymosin beta-4 — or from a formulation combining multiple ingredients, as with the GHK hair trial, that distinction is stated directly rather than smoothed over.

Third, community-reported effects are kept separate from clinical findings, always. Every passage describing what research-use communities report about a compound is labeled clearly as such: self-reported, unverified, and never a substitute for a controlled study.

What it is not

Southern Peptide Co is not a pharmacy, a clinic, a telehealth service, or a peptide vendor. It does not sell, source, or broker any compound, and has no referral or affiliate relationship with any supplier, clinic, or manufacturer. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any person.

GHK-Cu's topical cosmetic form is a legal, widely available skincare ingredient; none of the three compounds is an approved medicine for injectable or other systemic use, and none should be read as one. Readers with a medical question should consult a licensed healthcare provider in their own jurisdiction, and athletes subject to anti-doping testing should note that two of the three compounds discussed here carry WADA-prohibited status. Editorial correspondence on citations, corrections, or newly published research can be directed to the contact page; this briefing cannot respond to requests for medical advice.